Synthesis and evaluation of 18F-labeled PPARγ antagonists

Nuclear Medicine and Biology

Volumn 39, Issue 1, 2012, Pages 77-87

  Lee, Hsiaoju ^a   Chen, Delphine L ^a   Rothfuss, Justin M ^a   Welch, Michael J ^a   Gropler, Robert J ^a   Mach, Robert H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antagonist; Imaging agent; Peroxisome proliferator activated receptor ; PPAR

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 2 CHLORO N [4 (2 FLUOROETHOXY)PHENYL] 5 NITROBENZAMIDE F 18; 2 CHLORO N [4 (2 FLUOROETHYL)PHENYL] 5 NITROBENZAMIDE F 18; N [4 (2 FLUOROETHOXY)PHENYL] 2 METHOXY 5 NITROBENZAMIDE F 18; N [4 (2 FLUOROETHYL)PHENYL] 2 METHOXY 5 NITROBENZAMIDE F 18; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; RETINOID X RECEPTOR; UNCLASSIFIED DRUG; 2-CHLORO-5-NITROBENZANILIDE; ANILIDE; FLUORINE; LIGAND;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; RADIOCHEMISTRY; RAT; RECEPTOR AFFINITY; SCINTILLATION; TRANSGENIC MOUSE; ANIMAL; BIOASSAY; DISEASE MODEL; DRUG ANTAGONISM; HEART; HEART DISEASE; METABOLISM; METHODOLOGY; SCINTISCANNING; SYNTHESIS; TISSUE DISTRIBUTION; ZUCKER RAT;

ANILIDES; ANIMALS; BIOLOGICAL ASSAY; DISEASE MODELS, ANIMAL; FEMALE; FLUORINE RADIOISOTOPES; HEART; HEART DISEASES; LIGANDS; MALE; MICE; MICE, TRANSGENIC; POSITRON-EMISSION TOMOGRAPHY; PPAR GAMMA; RATS; RATS, ZUCKER; RETINOID X RECEPTORS; TISSUE DISTRIBUTION;

EID: 84855317584     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.07.002     Document Type: Article

References (21)

1. Chawla A., Repa J., Evans R., Mangelsdorf D. Nuclear receptors and lipid physiology: opening the X-files. Science 2001, 294:1866-1870.
2. Chawla A., Boisvert W.A., Lee C.H., Laffitte B.A., Barak Y., Joseph S.B., et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001, 7:161-171.
3. Szeles L., Torocsik D., Nagy L. PPARgamma in immunity and inflammation: cell types and diseases. Biochim Biophys Acta 2007, 1771:1014-1030.
4. Szanto A., Roszer T. Nuclear receptors in macrophages: a link between metabolism and inflammation. FEBS Lett 2008, 582:106-116.
5. Straus D.S., Glass C.K. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 2007, 28:551-558.
6. Sarraf P., Mueller E., Jones D., King F.J., DeAngelo D.J., Partridge J.B., et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med 1998, 4:1046-1052.
7. Ponferrada A., Caso J.R., Alou L., Colon A., Sevillano D., Moro M.A., et al. The role of PPARgamma on restoration of colonic homeostasis after experimental stress-induced inflammation and dysfunction. Gastroenterology 2007, 132:1791-1803.
8. Leesnitzer L.M., Parks D.J., Bledsoe R.K., Cobb J.E., Collins J.L., Consler T.G., et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 2002, 41:6640-6650.
9. Lee G., Elwood F., McNally J., Weiszmann J., Lindstrom M., Amaral K., et al. T0070907, a selective ligand for peroxisome proliferator-activated receptor γ, functions as an antagonists of biochemical and cellular activities. J Biol Chem 2002, 277:19649-19657.
10. Lee B.C., Lee K.C., Lee H., Mach R.H., Katzenellenbogen J.A. Synthesis and binding affinity of a fluorine-substituted peroxisome proliferator-activated gamma (PPARγ) ligand as a potential positron emission tomography (PET) imaging agent. Bioconjug Chem 2007, 18:507-513.
11. Lee B.C., Lee K.C., Lee H., Mach R.H., Katzenellenbogen J.A. Strategies for the labeling of halogen-substituted peroxisome proliferator-activated receptor γ ligands: potential positron emission tomography and single photon emission computed tomography imaging agents. Bioconjug Chem 2007, 18:514-523.
12. Kim S., Jonson S.D., Welch M.J., Katzenellenbogen J.A. Fluorine-substituted ligands for the peroxisome proliferator-activated receptor gamma (PPARγ): potential imaging agents for metastatic tumors. Bioconjug Chem 2001, 12:439-450.
13. 11C-GW7845, a positron-emitting agonist for peroxisome proliferator-activated receptor-gamma. J Nucl Med 2005, 46:1719-1726.
14. Lee B.C., Dence C.S., Zhou H., Parent E.E., Welch M.J., Katzenellenbogen J.A. Fluorine-18 labeling and biodistribution studies on peroxisome proliferator-activated receptor-gamma ligands: potential positron emission tomography imaging agents. Nucl Med Biol 2009, 36:147-153.
15. Lee H., Finck B.N., Jones L.A., Welch M.J., Mach R.H. Synthesis and evaluation of a bromine-76-labeled PPARgamma antagonist 2-bromo-5-nitro-N-phenylbenzamide. Nucl Med Biol 2006, 33:847-854.
16. Lapillonne H., Konopleva M., Tsao T., Gold D., McQueen T., Sutherland R.L., et al. Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Cancer Res 2003, 63:5926-5939.
17. Blanchard S., Cobb J.E., Collins J.L., Willson T.M. Nuclear receptor arylating compounds 2000, Glaxo Wellcome Inc., World Intellectual Property Organization WO/2000/055118, September 21, 2000.
18. Amemiya Y., Wakabayashi K., Takaishi S., Fukuda C. PPARγ modulators 2001, Sankyo Co. Ltd., World Intellectual Property Organization WO/2001/083427, August 11, 2001.
19. Sun S., Almaden J., Carlson T.J., Barker J., Gehring M.R. Assay development and data analysis of receptor-ligand binding based on scintillation proximity assay. Metab Eng 2005, 7:38-44.
20. Son N.H., Park T.S., Yamashita H., Yokoyama M., Huggins L.A., Okajima K., et al. Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J Clin Invest 2007, 117:2791-2801.
21. Oana F., Takeda H., Hayakawa K., Matsuzawa A., Akahane S., Isaji M., et al. Physiological difference between obese (fa/fa) Zucker rats and lean Zucker rats concerning adiponectin. Metabolism 2005, 54:995-1001.